- Home
- SSII vs PCRX Comparison
SSII vs PCRX Comparison
Compare SSII & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSII
- PCRX
- Stock Information
- Founded
- SSII N/A
- PCRX 2006
- Country
- SSII India
- PCRX United States
- Employees
- SSII N/A
- PCRX N/A
- Industry
- SSII
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SSII
- PCRX Health Care
- Exchange
- SSII Nasdaq
- PCRX Nasdaq
- Market Cap
- SSII 1.4B
- PCRX 1.2B
- IPO Year
- SSII N/A
- PCRX 2011
- Fundamental
- Price
- SSII $7.40
- PCRX $21.73
- Analyst Decision
- SSII
- PCRX Buy
- Analyst Count
- SSII 0
- PCRX 5
- Target Price
- SSII N/A
- PCRX $32.40
- AVG Volume (30 Days)
- SSII 156.2K
- PCRX 577.9K
- Earning Date
- SSII 10-28-2025
- PCRX 11-06-2025
- Dividend Yield
- SSII N/A
- PCRX N/A
- EPS Growth
- SSII N/A
- PCRX N/A
- EPS
- SSII N/A
- PCRX N/A
- Revenue
- SSII $36,066,457.00
- PCRX $705,848,000.00
- Revenue This Year
- SSII N/A
- PCRX $7.27
- Revenue Next Year
- SSII N/A
- PCRX $10.18
- P/E Ratio
- SSII N/A
- PCRX N/A
- Revenue Growth
- SSII 158.36
- PCRX 2.25
- 52 Week Low
- SSII $2.48
- PCRX $16.00
- 52 Week High
- SSII $22.42
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- SSII 44.25
- PCRX 41.07
- Support Level
- SSII $7.25
- PCRX $21.20
- Resistance Level
- SSII $10.00
- PCRX $22.70
- Average True Range (ATR)
- SSII 0.65
- PCRX 1.04
- MACD
- SSII -0.27
- PCRX 0.14
- Stochastic Oscillator
- SSII 7.27
- PCRX 56.25
About SSII SS Innovations International Inc.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.